Recruitment underway for Phase 2 trial of idiopathic PF inhalation therapy
LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News
